Since type 2 diabetes mellitus (T2DM) is associated with not only insulin resistance but also β-cell dysfunction and impaired insulin secretion [5], GPR40 has been considered as a therapeutic target for T2DM by increasing insulin secretion [6, 7]. The gene discussed is FFAR1; the disease is type 2 diabetes mellitus.